Clinical Trials Directory

Trials / Completed

CompletedNCT02560857

Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients

Status
Completed
Phase
Study type
Observational
Enrollment
151 (actual)
Sponsor
Deepali Kumar · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study will prospectively determine the clinical utility of non-pathogen specific cellular immunity assessment using the Quantiferon-Monitor to quantify the degree of immunosuppression. The investigators will use the results of the assay to predict whether patients develop opportunistic infections and predict organ rejection.

Detailed description

Solid organ transplant (SOT) recipients undergo life-long immunosuppression to prevent allograft rejection. However, this also puts patients at significant risk for opportunistic infection. The degree of immunosuppression varies for each individual and is likely influenced by a combination of clinical factors such as antirejection medication, comorbidities, patient age as well as the state of patient immune system. Thus far, there have been no standardized methods to quantify the degree of global immunosuppression. A new blood test (Quantiferon-Monitor) has been recently developed that might help predict the level of immune suppression. The purpose of this study is to determine whether this new test will help determine a person's level of immune suppression after organ transplant. This will be done by trying to relate the level of immunity with the development of infection or rejection. If the test for immunosuppression is helpful, it may help us to better take into account the differences in patients when designing therapy. Ultimately, it may help develop better ways for preventing infections and transplant rejections.

Conditions

Interventions

TypeNameDescription
OTHERQuantiferon-Monitor assayThe QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.

Timeline

Start date
2014-09-01
Primary completion
2016-09-01
Completion
2018-05-01
First posted
2015-09-25
Last updated
2018-06-20

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02560857. Inclusion in this directory is not an endorsement.